Our data demonstrated that higher titer anti-HBc predicts a higher risk of liver metastases and worse survival in anti-HBc positive patients with colorectal cancer undergoing curative surgical resection, which implies the close relationship between highly active replication of HBV and occurrence of CRLM. Here, KRT88P is linked to colorectal cancer.